- About WXPress
- WXPress is your window into the world of WuXi AppTec and our global partners.
- Sitemap
- Events
- Contact
- Please reach out with any business inquires.
- communications@wuxiapptec.com
© 2026 WuXi AppTec. All Rights Reserved.Privacy Policy
July 27, 2023 ~ July 27, 2023
8:00 AM – 10:00 AM PDT and 8:00 PM – 10:00 PM PDT
WuXi AppTec was honored to have hosted the BOLD Innovation That Matters: Episode 3 virtual event. Over 30 experts from the life science field joined us to share their bold ideas, bold actions, and progress in tackling global challenges related to cancer, CNS disorders, and rare diseases.
During the event, these experts had thought-provoking discussions on various topics, including Breaking Barriers in Cancer R&D, Overcoming CNS Challenges, and Leading the New Generation in Rare Disease Intervention. They also showcased the latest advancements in treatments for cancer, CNS disorders, and rare diseases. The discussions were led by some of the life science industry’s most inspiring thought leaders and CEOs. Their shared insights addressed innovative approaches to common scientific obstacles that can enable efficiencies across our collective pursuits of breakthroughs for patients.
We want to say a big thank you to all the guest speakers for sharing their valuable insights and knowledge with us. We also appreciate all of you who tuned in to participate and helped make this event such a great success!
WuXi AppTec is committed to fostering innovation as a dedicated enabler, a trusted partner, and an active contributor to advancing breakthroughs for patients. By working together, we can think boldly and act boldly in addressing global health challenges!
We look forward to seeing you at future WuXi AppTec online and in-person events!
Hui Cai, Program Chair and Vice President, WuXi AppTec
Jorge Conde, General Partner, Andreessen Horowitz
Sara Tolaney, Chief, Division of Breast Oncology, Dana-Farber Cancer Institute; Associate Professor of Medicine, Harvard Medical School
Jake Becraft, CEO & Co-Founder, Strand Therapeutics
Gina Chapman, President & CEO, CARGO Therapeutics
Neil Dhawan, CEO & Co-Founder, Totus Medicines
Brian Gladsden, CEO, Mosaic Therapeutics
Roberto Iacone, CEO, Alentis Therapeutics
Bent Jakobsen, CEO, Founder and Board Director, Accession Therapeutics
Lori Lyons-Williams, President & CEO, Abdera Therapeutics
Richard Markus, President & CEO, Dantari
Szabolcs Nagy, Co-Founder & CEO, Turbine
Bin Zou, Founder & CEO, Axcynsis Therapeutics; Adjunct Associate Professor, National University of Singapore
Rudolph Tanzi, Joseph P. and Rose F. Kennedy Professor of Neurology, Harvard Medical School; Vice-Chair, Neurology, MGH
Steve Yang, Co-CEO, WuXi AppTec
Stewart Campbell, CEO, Axial Therapeutics
Gong Chen, Founder, NeuExcell Therapeutics
Dee Datta, Co-Founder & CEO, Switch Therapeutics
Cuong Do, CEO, BioVie; Chairman, M6P Therapeutics
Amit Etkin, Founder & CEO, Alto Neuroscience
Carmine Stengone, President & CEO, Pipeline Therapeutics
Cedric Ververken, CEO, Confo Therapeutics
Brian Bronk, Head of Business Development, Neurology, Rare Diseases, Technology Platforms and R&D Transactions, Sanofi Partnering
Michael Hayden, CEO, Prilenia
Djordje Filipovic, CEO, AB2 Bio
Harri Järveläinen, COO, Ractigen Therapeutics
Nerissa Kreher, CMO, Entrada Therapeutics
Brian McVeigh, Chairman, CEO & Co-Founder, Code Biotherapeutics
Kristof Vercruysse, CEO, TargED Biopharmaceuticals
Hanadie Yousef, CEO & Co-Founder, Juvena Therapeutics
Richard Soll, Head of Boston Office and Senior Advisor of Strategic Initiatives, WuXi AppTec
